Uncertainty tolerance among experts involved in drug reimbursement recommendations: Qualitative evidence from HTA committees in Canada and Poland
Wiesława Dominika Wranik,
Liesl Gambold and
Health Policy, 2021, vol. 125, issue 3, 307-319
Drug reimbursement decisions often rely on health technology assessment (HTA). Increasingly, new drugs have limited clinical evidence and uncertain clinical benefit. Our goal was to describe how members of drug advisory committees and other stakeholders conceptualize and tolerate uncertainty and how they rationalize uncertainty tolerance.
Keywords: Health Technology Assessment; Uncertainty tolerance; Drug advisory committees; Reimbursement recommendations; Qualitative interviews (search for similar items in EconPapers)
References: View references in EconPapers View complete reference list from CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
Full text for ScienceDirect subscribers only
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:125:y:2021:i:3:p:307-319
Access Statistics for this article
Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput
More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().